Pascal Deschatelets - 09 Jan 2023 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Scientific Officer
Signature
/s/ David Watson, attorney-in-fact for Pascal Deschatelets
Issuer symbol
APLS
Transactions as of
09 Jan 2023
Net transactions value
-$503,565
Form type
4
Filing time
10 Jan 2023, 19:07:59 UTC
Previous filing
30 Dec 2022
Next filing
17 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $49,395 +18,500 +1.9% $2.67* 995,780 09 Jan 2023 Direct F1
transaction APLS Common Stock Sale $552,960 -12,000 -1.2% $46.08 983,780 09 Jan 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -18,500 -9.1% $0.000000 183,994 09 Jan 2023 Common Stock 18,500 $2.67 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This is a scheduled exercise and sale from a 10B5-1 trading plan.
F2 This stock option was granted on 12/5/2013 and is fully vested.